argenx (NASDAQ:ARGX) Upgraded at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of argenx (NASDAQ:ARGX) from a sell rating to a hold rating in a research note released on Wednesday, Marketbeat Ratings reports.

Several other equities analysts have also recently issued reports on ARGX. Wedbush restated an “outperform” rating and issued a $655.00 price target on shares of argenx in a research report on Tuesday, December 3rd. Oppenheimer boosted their target price on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial reissued a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Finally, William Blair restated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and a consensus target price of $687.00.

argenx Trading Up 4.1 %

ARGX stock opened at $604.96 on Wednesday. The business has a 50 day simple moving average of $638.53 and a 200-day simple moving average of $595.17. The company has a market capitalization of $36.76 billion, a P/E ratio of -687.45 and a beta of 0.59. argenx has a twelve month low of $349.86 and a twelve month high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. Research analysts predict that argenx will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARGX. GeoWealth Management LLC increased its holdings in argenx by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in shares of argenx in the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC raised its position in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after purchasing an additional 48 shares during the last quarter. FIL Ltd purchased a new stake in argenx in the 4th quarter valued at approximately $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in argenx during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.